EXPORT CITATION

Chapter-113 LA Appendage Closure for AF in Cardiodiabetes: Is the Outcome Different?

BOOK TITLE: Cardiodiabetes Update: A Textbook of Cardiology

Author
1. Singh Balbir
ISBN
9789352703043
DOI
10.5005/jp/books/14130_114
Edition
1/e
Publishing Year
2018
Pages
4
Author Affiliations
1. Escorts Heart Institute and Research Centre, New Delhi, India, Medanta Heart Institute, Medanta–The Medicity, Gurgaon, Haryana, India, Medanta—The Medicity, Haryana, India, Medanta–The Medicity, Gurugram, Haryana, India, Armed Forces Medical College, Pune, Maharashtra, India, Institute of Cardiology, Medanta, The Medicity, Gurgaon, Haryana, India, Medanta Hospital, Gurugram, Haryana, India, Medanta Heart Institute, Medanta—The Medicity, Gurugram, Haryana, India, Medanta – The Medicity, Gurugram, Haryana, India
Chapter keywords
Left atrial appendage, LAA, evolving therapy, oral anticoagulant, OAC, dual antiplatelet therapy, DAPT, antiplatelet therapy, transesophageal echocardiography, TEE, atrial fibrillation, AF

Abstract

Percutaneous left atrial appendage (LAA) occlusion is an evolving therapy, which should be taken into consideration in those patients with AF with a high stroke risk and contraindications for oral anticoagulant (OAC). This chapter aims at discussing the scope for LAA closure, the available LAA occlusion devices and their clinical evidence until now. This chapter covers the rationale for left atrial appendage occlusion, existing options of stroke prevention in atrial fibrillation, postprocedural treatment, clinical trial results, and potential indications of left atrial appendage (LAA) closure. Dual antiplatelet therapy (DAPT) (aspirin and clopidogrel) is prescribed for the first 45 days after LAA closure and clopidogrel can then be stopped. After 6 months, ASA treatment may or may not be stopped completely if no other indication for antiplatelet therapy exists.

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved